Bank of America Cuts Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $8.00

Werewolf Therapeutics (NASDAQ:HOWL) had its price target decreased by Bank of America from $9.00 to $8.00 in a research report released on Monday,Benzinga reports. Bank of America currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on HOWL. Wedbush lowered their target price on shares of Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating on the stock in a research note on Friday, May 9th. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $8.00.

Werewolf Therapeutics Price Performance

HOWL stock opened at $1.33 on Monday. The firm has a 50 day moving average of $1.24 and a 200-day moving average of $1.14. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. Werewolf Therapeutics has a 12 month low of $0.60 and a 12 month high of $4.18. The firm has a market capitalization of $60.82 million, a P/E ratio of -0.81 and a beta of 0.63.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. As a group, sell-side analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $409,000. Qube Research & Technologies Ltd purchased a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $48,000. Finally, Marshall Wace LLP purchased a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $113,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.